UPDATE 1-AstraZeneca ties up with Emergent BioSolutions to make COVID-19 vaccine in U.S.

Emergent BioSolutions Inc said on Thursday it signed an $87 million deal to make AstraZeneca Plc's experimental COVID-19 vaccine in the United States, boosting the British drugmaker's efforts to bring a vaccine to the market.